News & Insights
Company updates, client milestones and practical perspectives on commercializing life-science technologies.
UBC Updates
Company milestones, client developments and strategic activity from across the UBC network.
2026 · Fundraising & Commercialization
FreMon Scientific
UBC is supporting FreMon Scientific with fundraising and commercialization around ZipThaw, its dry thawing platform for blood products and advanced biologics. During 2026, FreMon reported additional third-party validation in cell therapy and expanding use across blood banking, clinical and research settings. UBC’s work spans fundraising support, investor readiness, commercialization and growth planning.
2025 · Operator & Transaction
ORFLO Joins Precision Cell Systems
UBC’s ownership and operating work with ORFLO progressed to a strategic combination with S2 Genomics under Precision Cell Systems. The transaction extended UBC’s involvement from commercial strategy and execution through ownership, operating leadership and board-level value creation.
2024 · Operating Growth
ORFLO Expands to San Diego
ORFLO relocated its headquarters to the San Diego area as part of UBC’s continued development of the company. The move brought ORFLO closer to customers, commercial talent and strategic partners while creating a stronger operating base for the next phase of growth.
2022 · Acquisition & Commercialization
United BioChannels Acquires ORFLO Technologies
UBC acquired ORFLO Technologies from Gemini BioProducts and moved from advisory work into direct ownership and operating leadership. The transaction was designed to apply UBC’s Modular Method to strengthen commercial focus, customer engagement and market share, with financing support from BroadOak Capital Partners.
2021 · Commercial Strategy & Sales Execution
Cell Microsystems Partners with United BioChannels
Cell Microsystems engaged UBC to support commercial strategy and sales execution as the company expanded market development around its cell-selection and single-cell workflow technologies.
Commercial Insights
Lessons from UBC’s work in market assessment, positioning, commercialization and growth—focused on turning market evidence into action.
Data Doesn’t Lie: Scaling the Right Mountain Part II
Our previous blog detailed the ideal structure of sales data and insightful questions to ask during comprehensive pipeline reviews. Once all historical and current sales data has been gathered and analyzed, it is powerful to inform future commercial programs. When...
Scaling the Right Mountain: Identifying High Value Markets You Can Lead
Key activities such as market evaluation, product positioning and alignment of leadership goals are crucial first steps to commercial success. To continue the development of an optimal commercial strategy, consider past commercial successes and failures. Historical...
The Art of Identifying Opportunity: Choosing Your Market
In previous posts, we have discussed the importance of positioning and market research in crafting a viable commercial strategy. In this blog, we will review an essential component of establishing a commercial foothold and verifying market opportunity: completion of a...
The Internal Assessment: The Key to an Effective Sales Team
So Your Sales Team Isn’t Selling? Developing biotechnology requires scientific expertise but once the product is developed and ready for the market, the next step is to hire an expert sales team, right? Then why isn’t your product selling as well as you expected?...
The United BioChannels Positioning Brief: Your Key to Commercial Success
Are you considering launching your product into a new market? Is your product not gaining the market traction you expected? Do you want investors to believe in your product as much as you do? The Positioning Brief: Driving Commercial Strategy Product market fit...
Have a commercial question?
Many UBC engagements begin with a specific market, growth or execution question. If something here connects with a challenge you are working through, start a conversation with us.
United BioChannels
Copyright 2026